GOSS Gossamer Bio Inc

SVB Securities analyst Joseph Schwartz reiterated a Buy rating on Gossamer Bio (GOSS - Research Report) on November 28 and set a price target of $15.00. The company's shares closed yesterday at $8.56.Schwartz covers the Healthcare sector, focusing on stocks such as BioMarin Pharmaceutical, Sarepta Therapeutics, and Ascendis Pharma. According to TipRanks, Schwartz has an average return of -17.4% and a 32.30% success rate on recommended stocks. Currently, the analyst consensus on Gossamer Bio is a Strong Buy with an average price target of $18.33, representing an 114.14% upside. In a report released on November 18, Wedbush also maintained a Buy rating on the stock with a $19.00 price target.
https://www.tipranks.com/news/blurbs/gossamer-bio-goss-receives-a-buy-from-svb-securities-2?utm_source=advfn.com&utm_medium=referral